both 1:1000, Thermo Fisher Scientific)
GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress
utility patent has a statutory term of 20 years from the earliest effective filing date
Work in the authors laboratory was supported by funds from Karolinska Institutet, the Swedish Research Council, the Family Erling-Persson Foundation, the Novo Nordisk Foundation, the Stichting af Jochnick Foundation, the Swedish Diabetes Association, Scandia Insurance Company Limited, the Diabetes Research and Wellness Foundation, the Berth von Kantzows Foundation, the Strategic Research Program in Diabetes at Karolinska Institutet, the European Research Council grant ERC-2018-AdG834860EYELETS, the Swedish Foundation for Strategic Research and the Knut and Alice Wallenberg Foundation